CATALYST PHARMACEUTICALS INC share price logo

CATALYST PHARMACEUTICALS INC

US: CPRX

$31.49

+0.01

(+0.03%)

as on

Bell Icon

This instrument is not available for trading on the INDmoney app on 14 Jul 2026

CATALYST PHARMACEUTICALS INC Stock Performance

as on July 15, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $31.48
    $31.50
    downward going graph

    0.03%

    Downside

    0.03%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $19.90
    $32.56
    downward going graph

    36.81%

    Downside

    3.40%

    Upside

    downward going graph

CATALYST PHARMACEUTICALS INC share price movements today

Previous Close
$31.48
Open
$31.49
Volume
4.8M
Day's Low - High
$31.48 - $31.50
52 Week Low - High
$19.90 - $32.56

CATALYST PHARMACEUTICALS INC Historical Returns

1 Month Return
0 %
3 Month Return
0 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

CATALYST PHARMACEUTICALS INC Stock Fundamentals & Key Indicators

Check CATALYST PHARMACEUTICALS INC market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$-

EPS (TTM)

0

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0.00

EBITDA

-

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

0.00%

CATALYST PHARMACEUTICALS INC vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of CATALYST PHARMACEUTICALS INC with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
CATALYST PHARMACEUTICALS INC image
CATALYST PHARMACEUTICALS INC
Buy$-NANA0.00%0.00%
Revolution Medicines image
Revolution Medicines
StrongBuy$41.0B468.83%-21.590.00%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$141.7B192.56%32.2786.04%0.00%
Regeneron image
Regeneron
Buy$95.5B47.41%19.7685.77%0.40%

Analyst Recommendation on CATALYST PHARMACEUTICALS INC Stock

Based on 13 analysts

BUY

92.31%

Buy

7.69%

Hold

0.00%

Sell

Based on 13 analysts, 92.31% of analysts recommend a 'BUY' rating for CATALYST PHARMACEUTICALS INC. Average target price of $31.67

CATALYST PHARMACEUTICALS INC Share Price Target

Get share price movements and forecasts by analysts on CATALYST PHARMACEUTICALS INC.

What analysts predicted

0.57%UPSIDE

Target Price

$31.67

Current Price

$31.49

Analyzed by

13 Analysts

Target

$31.67

CATALYST PHARMACEUTICALS INC target price $31.67, a slight upside of 0.57% compared to current price of $31.49. According to 13 analysts rating.

CATALYST PHARMACEUTICALS INC Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
110
98
122
128
141
141
146
148
152
149
Gross Profit
94
85
107
109
120
123
116
123
126
125
Operating Income
-
-
-
-
-
-
-
-
-
-
EBITDA
-
-
-
-
-
-
-
-
-
-
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-
-
-
-
-
-
-
-
-
-
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
34
23
40
43
55
56
52
52
52
63
Net Profit Margin
31.51%
23.63%
33.24%
34.10%
39.44%
40.12%
35.55%
35.57%
34.53%
42.66%

CATALYST PHARMACEUTICALS INC Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
0
102
119
140
214
398
491
588
Gross Profit
0
0
0
87
102
118
179
346
422
501
Operating Income
-
-
-
-
-
-
-
-
-
-
EBITDA
-
-
-
-
-
-
-
-
-
-
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-
-
-
-
-
-
-
-
-
-
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-18
-18
-34
31
74
39
83
71
163
214
Net Profit Margin
0.00%
0.00%
-6800.70%
31.16%
62.97%
28.03%
38.79%
17.93%
33.33%
36.39%

Global Institutional Holdings in CATALYST PHARMACEUTICALS INC

Check out the Institutions with significant holdings in CATALYST PHARMACEUTICALS INC.

Funds
Holdings
Qube Research & Technologies
0.83%
Vanguard Group Inc
6.88%
Geode Capital Management, LLC
2.43%
Morgan Stanley - Brokerage Accounts
2.19%
Boston Partners Global Investors, Inc
1.40%
See all

CATALYST PHARMACEUTICALS INC News & Key Events

  • img

    Today's Timeline - 25 March

    Wed, 05:53 PM

    -

    Catalyst Pharmaceuticals' 2026 EPS estimates rise from $2.55 to $2.87; Zacks Rank #1 (Strong Buy).

Insights on CATALYST PHARMACEUTICALS INC

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, CPRX stock has moved up by 21.6%

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, 52.69M → 63.73M (in $), with an average increase of 17.3% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 591.8% return, outperforming this stock by 446.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 380.3% return, outperforming this stock by 331.6%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 152.61M → 149.38M (in $), with an average decrease of 2.1% per quarter

About CATALYST PHARMACEUTICALS INC

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
OrganisationCATALYST PHARMACEUTICALS INC

FAQs

What is CATALYST PHARMACEUTICALS INC share price today?

CATALYST PHARMACEUTICALS INC share price today is $31.49 as on at the close of the market. CATALYST PHARMACEUTICALS INC share today touched a day high of $31.50 and a low of $31.48.

What is the 52 week high and 52 week low for CATALYST PHARMACEUTICALS INC share?

CATALYST PHARMACEUTICALS INC share touched a 52 week high of $32.56 on and a 52 week low of $19.90 on . CATALYST PHARMACEUTICALS INC stock price today i.e. is closed at $31.49,which is 3.29% down from its 52 week high and 58.24% up from its 52 week low.

How to invest in CATALYST PHARMACEUTICALS INC Stock (CPRX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for CATALYST PHARMACEUTICALS INC on INDmoney app. Click on Buy button.

What is the minimum amount required to buy CATALYST PHARMACEUTICALS INC Stock (CPRX) from India?

Indian investors can start investing in CATALYST PHARMACEUTICALS INC (CPRX) shares with as little as ₹94.9000015258789 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.00 in CATALYST PHARMACEUTICALS INC stock (as per the Rupee-Dollar exchange rate as on ). Based on CATALYST PHARMACEUTICALS INC share’s latest price of $31.49 as on July 15, 2026 at 8:45 am IST, you will get 0.3176 shares of CATALYST PHARMACEUTICALS INC. Learn more about fractional shares .